Scientists at Northwestern University have developed a new approach that directly combats the progression of neurodegenerative diseases like Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
In these devastating illnesses, proteins misfold and clump together around brain cells, which ultimately leads to cell death. The innovative new treatment effectively traps the proteins before they can aggregate into the toxic structures capable of penetrating neurons. The trapped proteins then harmlessly degrade in the body.
The “clean-up” strategy significantly boosted the survival of lab-grown human neurons under stress from disease-causing proteins.
The study, “Supramolecular copolymerization of glycopeptide amphiphiles and amyloid peptides improves neuron survival,” was published in the Journal of the American Chemical Society.
“Our study highlights the exciting potential of molecularly engineered nanomaterials to address the root causes of neurodegenerative diseases,” said Northwestern’s Samuel I. Stupp, the study’s senior author. “In many of these diseases, proteins lose their functional folded structure and aggregate to make destructive fibers that enter neurons and are highly toxic to them.
“By trapping the misfolded proteins, our treatment inhibits the formation of those fibers at an early stage. Early stage, short amyloid fibers, which penetrate neurons, are believed to be the most toxic structures. With further work, we think this could significantly delay progression of the disease.”
A pioneer in regenerative medicine, Stupp is the Board of Trustees Professor of Materials Science and Engineering, Chemistry, Medicine and Biomedical Engineering at Northwestern, where he has appointments in the McCormick School of Engineering, Weinberg College of Arts and Sciences and Feinberg School of Medicine. He is also the founding director of the Center for Regenerative Nanomedicine (CRN). Zijun Gao, a Ph.D. candidate in Stupp’s laboratory, is the paper’s first author.
The Stupp group led the development and characterization of the new therapeutic materials. Co-corresponding author Zaida Alvarez—a researcher at the Institute for Bioengineering of Catalonia (IBEC) in Spain, former postdoctoral fellow in Stupp’s laboratory and current visiting scholar at CRN—led testing of the therapies in human neurons.
A sugar-coated solution
According to the World Health Organization, as many as 50 million people worldwide might have a neurodegenerative disorder. Most of these diseases are characterized by the accumulation of misfolded proteins in the brain, leading to the progressive loss of neurons. While current treatments offer limited relief, a dire need for new therapies remains.
To tackle this challenge, the researchers turned to a class of peptide amphiphiles, pioneered by the Stupp laboratory, that contain modified chains of amino acids. Peptide amphiphiles are already used in well-known pharmaceuticals, including semaglutide, or Ozempic.
In fact, the Northwestern investigators developed a similar molecule in 2012 that boosted insulin production.
“The advantage of peptide-based drugs is that they degrade into nutrients,” Stupp said. “The molecules in this novel therapeutic concept break down into harmless lipids, amino acids and sugars. That means there are fewer adverse side effects.”
Over the years, Stupp’s research group has designed many peptide-based materials for different therapeutic purposes. To develop a peptide amphiphile to treat neurodegenerative diseases, his team added an extra ingredient: a natural sugar called trehalose.
“Trehalose is naturally occurring in plants, fungi and insects,” Gao said. “It protects them from changing temperatures, especially dehydration and freezing. Others have discovered trehalose can protect many biological macromolecules, including proteins. So, we wanted to see if we could use it to stabilize misfolded proteins.”
Instability is key
When added to water, the peptide amphiphiles self-assembled into nanofibers coated with trehalose. Surprisingly, the trehalose destabilized the nanofibers. Although it seems counterintuitive, this decreased stability exhibited a beneficial effect.
By themselves, the nanofibers are strong and well-ordered—and resistant to rearranging their structure. That makes it more difficult for other molecules, like misfolded proteins, to integrate into the fibers. Less stable fibers, on the other hand, became more dynamic—and more likely to find and interact with toxic proteins.
“Unstable assemblies of molecules are very reactive,” Stupp said. “They want to interact with and bond to other molecules. If the nanofibers were stable, they would happily ignore everything around them.”
Searching for stability, the nanofibers bonded to amyloid-beta proteins, a key culprit implicated in Alzheimer’s disease. But the nanofibers didn’t just stop the amyloid-beta proteins from clumping together. The nanofibers fully incorporated the proteins into their own fibrous structures—permanently trapping them into stable filaments.
“Then, it’s no longer a peptide amphiphile fiber anymore,” Stupp said. “But a new hybrid structure comprising both the peptide amphiphile and the amyloid-beta protein. That means the nasty amyloid-beta proteins, which would have formed amyloid fibers, are trapped. They can no longer penetrate the neurons and kill them. It’s like a clean-up crew for misfolded proteins.
“This is a novel mechanism to tackle the progression of neurodegenerative diseases, such as Alzheimer’s, at an earlier stage. Current therapies rely on the production of antibodies for well-formed amyloid fibers.”
Improving neuron survival
To assess the therapeutic potential of the new approach, the scientists conducted laboratory tests using human neurons derived from stem cells. The results showed the trehalose-coated nanofibers significantly improved the survival of both motor and cortical neurons when exposed to the toxic amyloid-beta protein.
Stupp says the novel approach of using unstable nanofibers to trap proteins offers a promising avenue for developing new and effective therapies for Alzheimer’s, ALS and other neurodegenerative conditions. Much like cancer treatments combine multiple therapies—like chemotherapy and surgery or hormone therapy and radiation—Stupp said the nanotherapy might be most effective when combined with other treatments.
“Our therapy might work best when targeting diseases at an earlier stage—before aggregated proteins enter cells,” Stupp said. “But it’s challenging to diagnose these diseases at early stages. So, it could be combined with therapies that target later-stage symptoms of the disease. Then, it could be a double whammy.”
